HOME >> BIOLOGY >> NEWS
New approach limits damage after heart attack and improves survival, say Scripps Research scientists

A team led by scientists at The Scripps Research Institute has developed a potential new treatment for heart attacks. The therapy inhibits fluid leakage from cardiac blood vessels following a heart attack and thereby significantly prevents long-term heart damage and improves survival.

"Immediately following a heart attack, blood vessels near the site of injury become leaky, causing fluid accumulation in the healthy area of the heart surrounding the injured site," says Immunology Professor David A. Cheresh, Ph.D., who led the research with postdoctoral fellow Sara Weis, Ph.D at The Scripps Research Institute. This permeability response is devastating to normal heart tissue.

"Until now," continues Cheresh, "nobody has realized the extent to which this leak response damages heart tissue and causes long-term tissue injury. We discovered a way to block this process and thus save heart tissue from irreversible damage."

Using laboratory models that are designed to mimic the pathology of heart attacks in humans, Cheresh, Weis, and their colleagues found that a single dose of a compound designed to block this fluid leakage (which is called edema) can, even if given as late as six hours after the event, drastically reduce tissue injury and increase long-term survival following a heart attack.

A biopharmaceutical company, TargeGen Inc. in San Diego, is finalizing preclinical studies to translate these initial research findings into practical human therapies. Using extensive preclinical models that mirror human heart attacks, TargeGen scientists report that 40 to 60 percent reductions in infarct (tissue injury) size with a small molecule drug that inhibits vascular leak and edema. Based on the encouraging preclinical efficacy and safety studies, TargeGen plans to initiate a combined Phase I/II human clinical trial in the second half of 2004 for patients undergoing an acute heart attack.

In addition to Cheresh and Weis, the team
'"/>

Contact: Jason Bardi
jasonb@scripps.edu
858-784-9254
Scripps Research Institute
15-Mar-2004


Page: 1 2 3 4 5

Related biology news :

1. Belgian researchers explore revolutionary approach to angiogenesis
2. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
3. Researchers recommend new approach to combat drug-resistant staph infections
4. U. Iowa muscular dystrophy discovery may lead to new treatment approaches
5. New research suggests therapeutic approach for autoimmune diseases
6. New approach offers potential drug-discovery shortcut
7. Steroid-coated DNA represents new approach to gene delivery
8. Two-drug approach might shorten painful labor, reduce Caesarean sections
9. Death-defying approach devised by Penn scientists to prevent cell apoptosis
10. Smallpox in 50-year-old tissues detected by integrated diagnostics approach
11. One-size-fits-all approach to nutrition recommendations may soon be outdated

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/18/2019)... ... March 18, 2019 , ... uBiome, ... industry and the third highest quality portfolio following Seres Health and Nestle, as ... Christian Moser, and Theodor Myfleler. uBiome executives Dr. Jessica Richman, PhD, co-founder and ...
(Date:3/14/2019)... , ... March 13, 2019 , ... Bode Technology (Bode), a leading provider ... on more than 100,000 sexual assault kits. As thousands of untested kits are identified ... sexual assault kit backlogs . Bode has tested more than 50,000 kits in the ...
(Date:3/12/2019)... SANTA CLARA, Calif. (PRWEB) , ... March 12, ... ... world leader in strong multi-factor authentication and combined technology all-in-one smart cards, announced ... combined with FIDO strong authentication: the Fingerprint Biometric and Dynamic CVV Payment cards. ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... WHITEHOUSE, N.J. (PRWEB) , ... March 19, 2019 , ... ... and is a great opportunity to see the most cutting-edge cancer research. The Visikol ... work with 3D cell culture assays as well as their digital ...
(Date:3/19/2019)... ... ... will review strategies for data management in modular and adaptive clinical trials. , Participants will:, ... 30 percent, reducing cost while increasing quality, achieving clinical site set-up faster , ... reducing risk and impact on trial success, trial teams, and trial execution , ...
(Date:3/15/2019)... (PRWEB) , ... March 15, ... ... of 100% equity in American Process Inc. and affiliate companies including AVAPCO ... Biorefinery in Alpena Michigan, the Thomaston Biorefinery and R&D center in Thomaston, ...
(Date:3/14/2019)... DESERT, Calif. (PRWEB) , ... March 14, 2019 ... ... issued a press release announcing that its Canadian partner, the Eye Machine Canada ... Canada, using Nova Oculus’s pioneering technology for treating Age-Related Macular Degeneration (AMD). , ...
Breaking Biology Technology:
Cached News: